PubRank

Thorbald van Hall

Author PubWeight™ 35.19‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 2011 2.02
2 Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res 2010 1.59
3 DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 2007 1.45
4 Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res 2009 1.26
5 Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 2011 1.24
6 Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A 2009 1.24
7 Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol 2010 1.24
8 Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem 2007 1.23
9 Therapeutic cancer vaccines. J Clin Invest 2015 1.23
10 HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A 2011 1.17
11 In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol 2010 1.15
12 Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 2010 1.06
13 The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. J Exp Med 2009 1.05
14 Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol 2011 1.02
15 Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol 2013 0.96
16 Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol Immunol 2012 0.94
17 Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol 2013 0.93
18 Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res 2005 0.92
19 Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses. Mol Immunol 2011 0.89
20 Characterization of antigen-specific immune responses induced by canarypox virus vaccines. J Immunol 2007 0.88
21 CD8+ T cell responses against TAP-inhibited cells are readily detected in the human population. J Immunol 2010 0.86
22 Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. J Immunol 2012 0.85
23 TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. J Clin Invest 2016 0.85
24 Proline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptides. Eur J Immunol 2013 0.84
25 Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. J Immunol 2011 0.83
26 Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires. Eur J Immunol 2011 0.83
27 Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients. Invest Ophthalmol Vis Sci 2009 0.82
28 New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation. J Immunol 2013 0.82
29 Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells. PLoS One 2012 0.81
30 Importance of TAP-independent processing pathways. Mol Immunol 2012 0.81
31 Targeting host B-cell immune responses by persistent donor NK-cell alloreactivity following nonmyeloablative allogeneic stem cell transplantation. Blood 2007 0.81
32 Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 2002 0.79
33 Application of multicolor fluorescence in situ hybridization analysis for detection of cross-contamination and in vitro progression in commonly used murine tumor cell lines. Cancer Genet Cytogenet 2002 0.78
34 Infiltrating CTLs are bothered by HLA-E on tumors. Oncoimmunology 2012 0.78
35 Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. Cancer Res 2007 0.77